Document:

EX-10.1

 Exhibit 10.1 

AMENDMENT NO. 1 TO 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 1 (this “Amendment No. 1”), dated as of February 25, 2022
(the “Effective Date”), is entered into between Ronald A. Rittenmeyer (the “Executive”) and Tenet Healthcare Corporation (the “Company”). 

RECITALS 
 WHEREAS,
the Company and the Executive are parties to that certain Amended and Restated Employment Agreement, dated as of September 1, 2021 (the “Agreement”); 

WHEREAS, pursuant to Section 16 of the Agreement, the Agreement may be amended or waived only with the prior written consent of
the Company and Executive; and 
 WHEREAS, the Company and Executive desire to amend the Agreement as set forth herein, effective as
of the Effective Date. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 
 1. Capitalized Terms. Capitalized terms
used and not otherwise defined herein shall have the meanings assigned to them in the Agreement. 
 2. Amendments. 

(a) The first sentence of Section 1 of the Agreement is hereby amended and restated as follows: 

“The Company agrees to employ Executive pursuant to the terms of this Agreement, and Executive agrees to be so employed, for a term
commencing as of the Effective Date and ending on December 31, 2025 (the “Term”).” 
 (b) Section 2(a) of
the Agreement is hereby amended and restated as follows: 
 “During the portion of the Employment Period commencing on the Effective
Date and ending on December 31, 2023 (the “Initial Period”), Executive will serve as the Company’s Executive Chairman and Executive will report directly to the Board of Directors of the Company (the
“Board”). During the Initial Period, Executive will also serve as the Executive Chairman of the Board. During the portion of the Employment Period from and after January 1, 2024 (the “Subsequent Period”),
Executive will serve as a senior advisor to the Chief Executive Officer and the Board and perform senior-level advisory services as reasonably requested by the Chief Executive Officer and the Board for a period of time not to exceed eight
(8) days per month.” 
 (c) The first sentence of Section 3(b) of the Agreement is hereby amended and restated as follows:

 “Executive shall be eligible to receive an annual incentive payment (the “Annual Bonus”) based on a target bonus
opportunity during the Initial Period of no less than 150% of Executive’s Base Salary and 100% of Executive’s Base Salary during the Subsequent Period, with the actual Annual Bonus amount calculated based upon the attainment of one or more
performance-based objectives established by the Board or the Human Resources Committee thereof (the “Committee”) in its sole discretion.” 

 (d) Section 4(b)(v) of the Agreement is hereby amended and restated as follows: 

“any Annual Bonus for any preceding fiscal year which, as of the Termination Date, has not been paid, and which would have been paid but
for Executive’s termination of employment, such Annual Bonus to be paid at the same time as annual bonuses for such fiscal year are generally payable to other senior executives of the Company (the “Prior Year Bonus”);”

 (e) Section 4(b)(vi) of the Agreement is hereby amended and restated as follows: 

“a pro-rata portion of the Annual Bonus Executive would have earned for the performance year in
which the Termination Date occurs based on actual performance, with such pro-rata portion determined based on the quotient determined by dividing the number of days between the beginning of the performance
period in which such termination occurs and the Termination Date, divided by 365 (the “Pro-Rata Annual Bonus”), which amount shall be paid at such time annual bonuses are paid to other senior
executives of the Company;” 
 (f) Section 4(b)(vii) of the Agreement is hereby amended and restated as follows: 

“a lump sum payment equal to the sum of (x) a pro-rata portion of the Annual Bonus Executive
would have earned for the performance year in which Termination Date occurs based on the higher of actual or target performance, with such pro-rata portion determined based on the quotient determined by
dividing the number of days between the Termination Date and the conclusion of the performance period in which such termination occurs, divided by 365 (the “Pro-Rata Target Bonus”), and
(y) a pro-rata portion of the Annual Bonus for any performance year remaining during the Employment Period that begins following the Termination Date based on target performance, with such pro-rata portion determined based on the quotient determined by dividing the number of days between the beginning of the performance year and the conclusion of the Term, divided by 365 (the “Pro-Rata Remaining Bonus”), payable on the first regularly scheduled payroll period following the Termination Date;” 

3. Entire Agreement. This Amendment No. 1 shall only serve to amend and modify the Agreement to the extent specifically provided
herein. All terms, conditions, provisions and references of and to the Agreement which are not specifically modified, amended and/or waived herein shall remain in full force and effect and shall not be altered by any provisions herein contained. As
of the Effective Date, this Amendment No. 1 shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter of this Amendment No. 1
in any way other than the Agreement, the agreements referenced herein or in the Agreement, and any agreement which by its terms continues beyond the Executive’s termination of employment. 

4. Amendment and Waiver. This Amendment No. 1 shall not be amended, modified or supplemented except by a written instrument signed
by the parties hereto. The failure of a party to insist on strict adherence to any term of this Amendment No. 1 on any occasion shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to
that term or any other term of this Amendment No. 1. No waiver of any provision of this Amendment No. 1 shall be construed as a waiver of any other provision of this Amendment No. 1. Any waiver must be in writing. 

  
 - 2 - 

 5. Binding Effect. This Amendment No. 1 shall inure to the benefit of, and be
binding upon, the successors, administrators, heirs, legal representatives and assigns of Executive, and the successors and assigns of the Company. 

6. Counterparts. This Amendment No. 1 may be executed and delivered (including by facsimile, “pdf” or other electronic
transmission) in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. 

[Signature Page Follows] 

  
 - 3 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 as of the
Effective Date. 
  

			
	TENET HEALTHCARE CORPORATION
		
	By:	 	/s/ Thomas Arnst
	Name:	 	Thomas Arnst
	Title:	 	Executive Vice President, Chief Administrative
		 	Officer and General Counsel
	
	RONALD A. RITTENMEYER
	
	/s/ Ronald A. Rittenmeyer

 [Signature Page to Amendment No. 1 to Employment Agreement]Exhibit 10.1

 

Convertible Loan Agreement

 

of February 20, 2022

 

between

 

		1.	Cormorant Private Healthcare Fund IV. L.P.

200 Clarendon St., 52nd Floor

Boston, MA 02116, USA

neb@cormorant-asset.com

(hereinafter “Lender ”)

 

and

 

		2.	MoonLake Immunotherapeutics AG

Dorfstrasse 29

6300 Zug, Switzerland

m.bodenstedt@moonlaketx.com
and j.santosdasilva@moonlaketx.com

(hereinafter
the “Borrower”)

 

and

 

		3.	Biotechnology Value Fund, L.P.

44 Montgomery Street, 40th
Floor

San Francisco, CA 94104, USA

loy@bvflp.com and kratky@bvflp.com

(hereinafter
“Existing Lender 1”)

 

		4.	Biotechnology Value Fund II, L.P.

44 Montgomery
Street, 40th Floor

San Francisco,
CA 94104, USA

loy@bvflp.com
and kratky@bvflp.com

(hereinafter “Existing
Lender 2”)

 

		5.	Biotechnology Value Trading Fund OS, L.P.

PO Box 309 Ugland House,
Grand Cayman

KY1-1104, Cayman
Islands

loy@bvflp.com
and kratky@bvflp.com

(hereinafter “Existing Lender
3” and together with the Existing Lender 1 and the Existing Lender 2, the “Existing Lenders”)

 

and

 

     

    Loan Agreement

    

 

		6.	Helix Acquisition Corp. 

c/o Cormorant Asset Management
LP

200 Clarendon Street, 52nd
Floor

Boston, MA 02116, USA

andy@cormorant-asset.com
and neb@cormorant-asset.com

(hereinafter “Investor”
or “Helix”)

 

(the Lender, the Borrower, the Existing
Lenders and the Investor each a “Party” and collectively the “Parties”)

 

    2

    Loan Agreement

    

 

TAble of contents

 

	Preamble	4
	1.	Definitions	5
	2.	Loan	5
	3.	Interest	5
	4.	Disbursement	5
	5.	Purpose	5
	6.	Term and Repayment	6
	7.	Events of Default	6
	8.	Security	7
	9.	Representations and Warranties	7
	10.	Covenants	7
	11.	Status and Subordination	8
	12.	Conversion	10
	13.	Shareholder and OPtion holder Consent	11
	14.	Roll-over	12
	15.	Undertakings and Consents of Existing Lenders AND THE BORROWER	12
	16.	Sale of Borrower Shares	13
	17.	Miscellaneous	13
	18.	Applicable law and jurisdiction	16
	Annex 1: Definitions	19
	Annex 2: Consent Declaration	22

 

    3

    Loan Agreement

    

 

Preamble

 

		A.	The Borrower is organized in the form of a Swiss stock corporation (Aktiengesellschaft) registered
with the commercial register of the Canton of Zug under the number CHE-433.093.536.

 

		B.	The Borrower’s core business is the research, development, manufacturing and marketing of biotechnological,
pharmaceutical and similar products in Switzerland and abroad.

 

		C.	The Borrower has an issued statutory share capital in the nominal amount of CHF 104,172.40, divided
into 1,040,724 fully paid-in registered shares with a nominal value of CHF 0.10 each, of which 361,528 are common shares (Stammaktien)
and 680,196 are series A preferred shares (Vorzugsaktien Kategorie A) (such shares, together with any shares of the Borrower issued
after the date of this Agreement, the “Shares”). The Borrower also has conditional share capital to support issuances
under the employee equity incentive plans allowing an increase of the nominal share capital by a maximum amount of CHF 2,847.20 by
issuing a maximum of 28,472 registered common shares; in addition and also to support issuances under the employee equity incentive plans
the Borrower holds 22,756 treasury shares (common shares (Stammaktien)).

 

		D.	On October 4, 2021, the Borrower entered into a business combination agreement with the Investor and the
shareholders of the Borrower (the “Business Combination Agreement”); a subscription agreement with the Investor, an
investment agreement with the Investor and the shareholders of the Borrower and certain other agreements in connection therewith (the
“Transaction”).

 

		E.	On October 15, 2021, the Borrower has entered into a loan agreement with the Existing Lenders, which was
amended on January 18, 2022 and February 15, 2022, under which the Existing Lenders have granted the Borrower subordinated loans in an
aggregate amount of USD 15,000,000 (the “Existing Loan Agreement”).

 

		F.	The Lender has committed to participate in the Investor underwritten PIPE financing in connection with
the Transaction (the “Lender PIPE Commitment”), conditioned on the Transaction Closing, for an investment amount of
USD 27,500,000.

 

		G.	The Borrower currently requires bridge financing in order to finance its business operations until the
contemplated closing of the Transaction.

 

    4

    Loan Agreement

    

 

Now, therefore,
the Parties agree as follows:

 

		1.	Definitions

 

Capitalized terms used in this Agreement
shall have the meaning as set forth in Annex 1.

 

		2.	Loan

 

Subject to the receipt by the Lender
of the duly executed consents of all existing shareholders of the Borrower (the "Shareholders") and all existing holders
of options to acquire shares of the Borrower (the "Option Holders") to this Agreement (as set out in further detail in
Section 13 and in the form of Annex 2) and to the other terms of this Agreement, the Lender hereby grants to the Borrower
a loan (the “Loan”) in the nominal amount of USD 15,000,000.

 

		3.	Interest

 

The Loan shall be interest-free.

 

		4.	Disbursement

 

Disbursement of the Loan by the Lender
shall be effected in one tranche as follows:

 

		●	the
                                            aggregate amount of USD 15,000,000, two business days following the delivery of the PDF copies
                                            of the consent declarations (duly executed by wet ink signatures) of all Shareholders and
                                            all Option Holders as further described in Section 13, to the Lender.

 

The Lender shall disburse the Loan
to the bank account of the Borrower as notified to the Lender for such purposes, free of any costs or charges.

 

		5.	Purpose

 

The Loan may be used for the financing
of general corporate purposes of the Borrower, including product and technology development, operations, sales and marketing, management
expenses, and salaries.

 

Unless repaid in whole, the Loan shall
not be used for the full or partial repayment of the outstanding amount under the Existing Loan Agreement, any other existing Financial
Indebtedness of the Borrower and/or any future loan agreement to be entered into by the Borrower with the Existing Lenders and/or any
third party.

 

    5

    Loan Agreement

    

 

		6.	Term and Repayment

 

The Loan is granted for a fixed period
of time until the earlier of (i) as soon as practicable after the Transaction Closing, but no later than two (2) business days, and (ii)
June 30, 2022 (the “Maturity Date”).

 

The Loan may be repaid in whole or
in part by the Borrower at any time prior to the Maturity Date.

 

If the Transaction Closing occurs
before the Maturity Date and if the Lender chooses to pursue the Roll-Over, the Roll-Over of the Loan as described and defined in Section
13 shall be effected and upon the completion of the Roll-Over, the Loan shall continue thereafter between the Investor (as new lender/assignee)
and the Borrower and the obligations of the Borrower shall continue vis-à-vis the Investor, and the Lender will no longer be a
Party to this Agreement and be due any obligations hereunder.

 

		7.	Events of Default

 

On and at any time after the occurrence
of any of the events listed hereafter (an “Event of Default”), but subject to any suspensive effect resulting from
the subordination pursuant to Section ‎11, the Lender may (but is
not obliged), by notice to the Borrower, declare that all or part of the Loan become due and payable within 30 calendar days of receipt
of such notice by the Borrower:

 

		a)	Illiquidity: the Borrower is unable or admits inability to pay its debts as they fall due, suspends making
payments on any of its debts or, by reason of actual or anticipated financial difficulties, commences negotiations with one or more of
its creditors with a view to rescheduling any of its indebtedness;

 

		b)	Insolvency: the Borrower is declared bankrupt by a court, applies for bankruptcy (Konkurs) or reorganization
(Nachlassstundung), or has a resolution passed for its winding-up, a creditor files a petition for bankruptcy (Fortsetzungsbegehren)
or any similar event or such event is immediately threatened;

 

		c)	Breach of Representations and Warranties: any representation or warranty set forth in Section ‎8
proves to have been inaccurate or misleading in any material respect;

 

		d)	Breach of Covenant: the Borrower breaches any of the covenants set forth in Section ‎10
and the consequences of such breach are not fully cured within 30 calendar days from the date of receipt of a respective notice by the
Borrower from the Lender; or

 

		e)	Change of Control: the Borrower consummates a Change of Control at any time while the Loan remains outstanding.

 

    6

    Loan Agreement

    

 

		8.	Security

 

The Loan shall not be secured.

 

		9.	Representations and Warranties

 

The Borrower, as per the date of this
Agreement, hereby represents and warrants to the Lender as follows:

 

		a)	the Borrower is a company duly incorporated and validly existing under the laws of Switzerland, and has
full power, authority and legal right to own its assets, to carry on its business as it is being conducted and to enter into and perform
its obligations under this Agreement;

 

		b)	the execution, delivery and performance by the Borrower of this Agreement (i) have been duly authorized
by all necessary corporate decisions and other measures, (ii) require no governmental or regulatory action, authorization or approval,
(iii) do not and will not violate or conflict with the provisions of the articles of incorporation or by-laws of the Borrower and (iv)
do not and will not result in a breach of or constitute a default under any agreement or obligation applicable to the Borrower or by which
the Borrower is bound;

 

		c)	the obligations of the Borrower under this Agreement constitute legal, valid and binding obligations of
the Borrower, enforceable in accordance with their terms; and

 

		d)	no Event of Default has occurred.

 

		10.	Covenants

 

The Borrower hereby covenants and
agrees vis-à-vis the Lender, that it:

 

		a)	unless repaid in whole, shall not use the Loan for the full or partial repayment of the outstanding amount
under the Existing Loan Agreement and/or any other existing or future Financial Indebtedness of the Borrower and/or any future loan agreement
to be entered into by the Borrower with the Existing Lenders and/or any third party;

 

    7

    Loan Agreement

    

 

		b)	shall not grant, create or permit to subsist any security interest, including personal securities (Personalsicherheiten)
such as a surety and guarantee, over any of its present or future assets or revenues, except for security interests arising by operation
of law or in the ordinary course of business;

 

		c)	shall not request the distribution of dividends or other distributions to shareholders (it being understood
that the power to set or not set the dividends lies inalienably with the general meeting of the shareholders); and

 

		d)	shall comply with all material laws and regulations applicable to the Borrower in all material respects.

 

		11.	Status and Subordination

 

Subject to the terms in this Section
11, the claims of the Lender against the Borrower under the Loan shall rank senior to other existing or future unsecured subordinated
obligations of the Borrower (incl. the Existing Loans).

 

The Lender hereby irrevocably and
unconditionally declares to the Borrower that its claims with respect to the Loan owed now or in the future (the “Relevant Subordinated
Claims”), shall be and are hereby subordinated to all current and future claims of creditors of the Borrower.

 

During such term the Relevant Subordinated
Claims shall be deferred (gestundet), the Relevant Subordinated Claims may not be fully or partially be repaid, set-off (but for
a set-off in connection with a capital increase by means by set-off to achieve a Conversion or another debt-to-equity swap (in German:
Verrechnungsliberierung)), novated or otherwise be fulfilled and no security interest may be created in relation to the Relevant
Subordinated Claims. The Relevant Subordinated Claims shall be listed separately in the financial statements of the Borrower. If the Borrower
is declared bankrupt by a court or if the Borrower makes a general assignment, arrangement or composition with or for the benefit of its
creditors, the Lender herewith waive its Relevant Subordinated Claims to the extent required to cover from the liquidation proceeds the
claims of the other creditors and the claims arising in connection with the liquidation procedure.

 

In the case of bankruptcy or debt
restructuring liquidation of the Lender, the Borrower is permitted to offset the Relevant Subordinated Claims of such Lender with the
Borrower’s claims against it.

 

The Lender acknowledges and agrees
that nothing in this Agreement shall be construed as to restrict the board of directors of the Borrower to notify the competent courts
in case of an equity shortfall in the sense of Article 725 para. 2 CO.

 

    8

    Loan Agreement

    

 

The subordination pursuant to this
Agreement shall automatically be terminated if any of the following events occur:

 

		a)	a Conversion is conducted, regardless of an equity shortfall in the sense of Article 725 para. 2 CO;

 

		b)	the Transaction Closing occurs and the Borrower declares in writing (PDF copies of such declaration, duly
executed with wet ink signatures, being sufficient) that after such Transaction Closing, the Borrower is not over indebted pursuant to
Art. 725 para 2 CO and has a positive net equity;

 

		c)	the Borrower declares in writing (PDF copy of such declaration, duly executed with wet ink signatures,
being sufficient) that the subordination be cancelled (aufheben), provided, however, that such cancellation shall only be effective
and binding upon the Parties, if financial statements of the Borrower which (i) are current and reflect the financial conditions of the
Borrower in all material aspects as of the date of the cancellation of the subordination and (ii) audited in accordance with the then
current Swiss Audit Standards (Schweizer Prüfungsstandards) show that all liabilities of the Borrower (including the amounts
owed by the Borrower under the Relevant Subordinated Claims and all other subordinated liabilities, if any) are sufficiently covered by
assets (in case the Borrower is subject to a full audit (ordentliche Revision), a summarizing audit report from the auditor without
a qualification in the sense of Article 725 para. 2 CO suffices to satisfy this requirement);

 

		d)	the Lender irrevocably waives any and all Relevant Subordinated Claims; or

 

		e)	the Borrower declares in writing (PDF copies of such declaration, duly executed with wet ink signatures,
being sufficient) that another creditor of comparable solvency (in German: Bonität) agrees to a subordination of its claims
against the Borrower of least the same amount as the Relevant Subordinated Claims to be released and at the same conditions as applicable
to the Relevant Subordinated Claims and as set forth in this Agreement.

 

The subordination pursuant to this
Agreement has been approved by the board of directors of the Borrower having given due consideration to the creditworthiness of the Lender.
The Lender confirms that sufficient net wealth is at its disposal to absorb a possible or complete loss of the Relevant Subordinated Claims.

 

    9

    Loan Agreement

    

 

		12.	Conversion

 

		12.1	Voluntary Conversion

 

If the Business Combination Agreement
is terminated pursuant to its Section 11.1 and if prior to the Maturity Date, an Equity Financing Round is consummated, the Lender is
entitled to convert the Loan into Conversion Shares of the Borrower if the Borrower does not repay the Loan before the consummation of
such Equity Financing Round (the "Voluntary Conversion"). For the avoidance of any doubt, the Voluntary Conversion shall
be implemented at the same time and in connection with the Equity Financing Round triggering the Voluntary Conversion.

 

The number of Conversion Shares issuable
upon the Voluntary Conversion shall be determined by dividing the Loan by the applicable Conversion Price.

 

		12.2	Mandatory Conversion

 

If the Business Combination Agreement
is terminated pursuant to its Section 11.1 and if the Loan has neither been repaid within 30 calendar days of the Maturity Date nor a
Voluntary Conversion has taken place, the Loan shall be mandatorily converted into Conversion Shares of the Borrower (the "Mandatory
Conversion" and the Voluntary Conversion, each a "Conversion").

 

The number of Conversion Shares issuable
upon Mandatory Conversion shall be determined by dividing the Loan by the applicable Conversion Price.

 

		12.3	Joint Provisions

 

The Lender hereby undertakes to take
all such actions as may be reasonably necessary or appropriate in order to implement the applicable Conversion, in particular to subscribe
for the respective number of Conversion Shares and to pay the relevant subscription price by setting off the relevant Loan.

 

Prior to the applicable Conversion
being implemented pursuant to this Agreement and as a condition precedent to the obligations of the Borrower under this Section ‎12,
the Lender undertakes to accede to the then current shareholders’ agreement in relation to the Borrower which may contain customary
rights and obligations of shareholders, including, for the avoidance of doubt, rights of first refusal, purchase rights, drag-along rights,
tag-along rights etc.

 

    10

    Loan Agreement

    

 

The Company undertakes and procures,
to the extent legally permissible, that the rights of the Lender under this Section ‎12
are fully honored. The Borrower shall accept the Lender as new shareholder with voting rights and will not claim any restriction on transferability
of shares on the grounds of the articles of association of the Borrower (Statuten). The Borrower undertakes to disclose to the
Lender all information reasonably necessary to ensure that the Lender can ascertain in due course the proper calculation of the Conversion
Price. To the extent required for the implementation of the applicable Conversion, the Borrower shall, in addition to its obligations
under Section 13, use best efforts to procure that the Borrower’s Shareholders take all actions and give all consents required to
allow for the Lender to become a shareholder according to the terms of this Agreement.

 

If the Borrower at any time or from
time to time after the date of this Agreement effects a share split, subdivision or consolidation of Shares, the Conversion Price and/or
other terms of the Conversion shall be adjusted so that the number of Conversion Shares will reflect such effects without detriment to
the Lender.

 

		13.	Shareholder and OPtion holder Consent

 

The Borrower shall obtain consent
in respect of this Agreement from its Shareholders and Option Holders by way of soliciting separate consent declarations as set out in
Annex 2 until February 28, 2022.

 

The Borrower shall obtain consent
in respect of this Agreement by way of soliciting separate consent declarations as set out in Annex 2 from any person that
will be offered to become a shareholder (the "Future Shareholders"), subject to applicable requirements or restrictions
set forth in the Business Combination Agreement and/or the respective implementing agreements in relation to the Transaction, until the
earlier of: (i) the Voluntary Conversion having been consummated, or (ii) the Mandatory Conversion having been consummated.

 

The Borrower shall deliver the PDF
copies of the consent declarations (duly executed by wet ink signatures) of all the Shareholders and all the Option Holders to the Lender
at the latest two business days before the planned disbursement of the Loan.

 

The Borrower shall deliver the PDF
copies of the consent declarations (duly executed by wet ink signatures) of the Future Shareholders two business days before the offer
to become a shareholder can be bindingly accepted by the Future Shareholder.

 

    11

    Loan Agreement

    

 

		14.	Roll-over

 

As part of the closing of the Transaction,
the Lender shall have the right to unilaterally assign and transfer this Agreement with any and all associated rights and claims thereunder
(incl. the claim for full repayment of the Loan) to the Investor in (partial) satisfaction of the Lender PIPE Commitment (the "Roll-Over").

 

In case the Lender chooses to pursue
the Roll-Over and to assign and transfer this Agreement (incl. the claim for full repayment of the Loan to the Investor) in (partial)
satisfaction of the Lender PIPE Commitment:

 

		(i)	the Investor undertakes to accept such assignment and transfer as (partial) satisfaction of the Lender
PIPE Commitment; and

 

		(ii)	the Borrower hereby consents to the assignment and transfer of this Agreement and hereby accepts Investor
as the lender as from the relevant Roll-Over date and any reference in this Agreement to the “Lender” shall henceforth be
construed accordingly.

 

In order to effect the Roll-Over,
each of Lender, Borrower and Investor undertakes to execute and deliver any documents and or to perform any actions required or reasonably
desirable to document and complete the Roll-Over in accordance with this Agreement and applicable law.

 

		15.	Undertakings and Consents of Existing Lenders AND THE BORROWER

 

The Existing Lenders:

 

		a)	herewith agree that the Loan ranks at any time senior to the Existing Loan Agreement;

 

		b)	herewith approve the entry into this Agreement by the Borrower and the discharge of the obligations of
the Borrower hereunder in accordance with the terms and conditions set forth herein;

 

		c)	herewith consent to the right of the Lender to assign and transfer this Agreement (incl. the claim for
full repayment of the Loan) to the Investor as provided for in Section 14 and confirm that if this Agreement (incl. the claim for full
repayment of the Loan) is assigned and transferred to the Investor all requisite consents and approvals of this Section ‎15
shall also be given for the benefit of the Investor; and

 

    12

    Loan Agreement

    

 

		d)	in order to achieve the Voluntary Conversion or Mandatory Conversion, as applicable, hereby irrevocably
undertake to the Lender and to the Borrower to adopt and/or procure the adoption of the necessary resolutions of the shareholders of the
Borrower to effect the conversion of the Loan in accordance with the terms of this Agreement and to waive any priority subscription rights
(Vorwegzeichnungsrechte) and subscription rights (Bezugsrechte) to the extent necessary to allow for the full implementation
of the Voluntary Conversion or the Mandatory Conversion, as applicable.

 

		16.	Sale of Borrower Shares

 

If Business Combination Agreement
is terminated pursuant to its Section 11.1 and if the shareholders of the Borrower decide to sell or are required under the then current
shareholders’ agreement to sell all their respective Shares in the Borrower (the “Exit”), the Lender shall, upon
request of the Company, sell, assign and transfer this Agreement with any and all associated rights and claims thereunder (incl. the claim
for full repayment of the Loan) to the purchaser of such Shares for a consideration equal to the nominal value of the Loan. Each Party
hereby consents in advance to such assignment and transfer.

 

In order to effect the Exit, each
of Lender, Existing Lender, Borrower and Investor undertakes to execute and deliver any documents and or to perform any actions required
or reasonably desirable to document and complete the assignment and transfer in connection with the Exit in line with this Agreement and
applicable law.

 

		17.	Miscellaneous

 

		17.1	Nature of Parties’ Rights and Obligations

 

Except as specifically provided otherwise
in this Agreement, the rights and obligations of the Parties hereunder shall be several (and not joint). Each of the Parties may exercise
and enforce their rights hereunder individually in accordance with this Agreement, and the non-performance by a Party shall not relieve
any other Party from performing its obligations under this Agreement, nor shall the non-defaulting Parties be liable for the non-performance
by the defaulting Party.

 

The obligations of the Parties hereunder
are contractual in nature and the Parties agree that they do not form, and this Agreement shall not be deemed to constitute, a simple
partnership pursuant to Art. 530 et seq. CO.

 

The Loan does not form, and they shall
not be deemed to constitute, a bond (Anleihensobligation) pursuant to Art. 3 lit. a no. 7 FinSA and/or Art. 1156 et seq. CO.

 

    13

    Loan Agreement

    

 

		17.2	Confidentiality

 

Each of the Parties agrees to keep
secret and confidential and not to use, disclose or divulge to any third party or to enable or cause any person to become aware of, any
of the terms and conditions of this Agreement, and any information exchanged among the Parties in connection with the investment in the
Borrower or pertaining to the business and the operation of the Borrower (all such information collectively “Confidential Information”).
The Parties shall ensure that their employees, directors and any other representatives as well as the advisors of each Party to whom any
such Confidential Information is entrusted comply with these restrictions.

 

The term Confidential Information
shall not include any information (i) which as of the time of its disclosure by a Party was already lawfully in the possession of the
receiving Party as evidenced by written records, or (ii) which at the time of the disclosure was in the public domain, or (iii) the disclosure
of which was previously explicitly authorized by the respective Party.

 

The non-disclosure obligation shall
not apply to any disclosure of Confidential Information required by law or regulations. In the event a disclosure of Confidential Information
is required by law or regulations (including, without limitation, for tax, audit or regulatory purposes), the disclosing Party shall use
all reasonable efforts to arrange for the confidential treatment of the materials and information so disclosed.

 

Each Party may use any Confidential
Information in accordance with this Agreement. But, subject to the terms hereof, each Party acknowledges and agrees that any Confidential
Information made available to it (including to any representative or advisor of such Party) by the Borrower or any other Party (including
their representatives or advisors) hereunder shall not be used by such Party other than (i) as permitted under this Agreement, (ii) for
the benefit of the Borrower, or (iii) for the respective Party’s assessment of the Borrower, and shall not be exploited by or for
the benefit of such Party or any of its Affiliates or third party.

 

    14

    Loan Agreement

    

 

It is acknowledged and agreed that
the Lender and the Existing Lenders may report regularly to its investors and/or any of its Affiliates on information pertaining to the
Borrower and the funding under this Agreement, any direct or indirect equity investment made or to be made in the Borrower in accordance
with its reporting obligations under its fund investment documents or to the extent required for legal, tax, audit or regulatory purposes.

 

Nothing herein shall restrict the
Borrower from granting third parties customary due diligence access for purposes of financial, commercial, strategic or similar transactions
(including for a subscription of Shares in the Borrower).

 

		17.3	Successors and Assigns

 

This Agreement shall be binding upon
and shall inure to the benefit of the Parties and their respective permitted successors and assigns, provided, however, that neither Party
shall be entitled to assign or transfer any of the rights or obligations hereunder to any other party, but for the assignment and transfer
of this Agreement from the Lender to the Investor, as provided for in Section 13 (Roll-Over) and any assignment and transfer of
this Agreement from the Lender to a purchaser of all the Shares as provided for in Section 16 (Sale of Borrower Shares).

 

		17.4	Costs and Expenses

 

Each Party shall bear its own costs
and expenses arising out of or incurred, and any taxes and fees imposed on it, in connection with this Agreement and all transactions
contemplated hereby.

 

		17.5	Notices

 

All notices and other communications
made or to be made under this Agreement shall be given in writing or electronic form and be delivered by post, courier or email to the
addresses indicated on the cover sheet, unless otherwise notified by a Party.

 

For the purpose of meeting a period
or deadline by the sender, a notice shall be deemed made when dispatched by the sender. For the purpose of triggering the start of a period
or deadline for the recipient, a notice shall be deemed made or received when it arrives at the recipient.

 

    15

    Loan Agreement

    

 

		17.6	Entire Agreement

 

This Agreement constitutes the entire
agreement among the Parties with respect to the subject matter hereof and supersedes any agreement or understanding with respect to the
subject matter hereof that may have been concluded between the Borrower, the Lender, the Investor and/or the Existing Lenders, as applicable,
prior to the date of this Agreement.

 

		17.7	Severability

 

If at any time any provision of this
Agreement or any part thereof is or be-comes invalid or unenforceable, then neither the validity nor the enforceability of the remaining
provisions or the remaining part of the provision shall in any way be affected or impaired thereby. The Parties agree to replace the invalid
or unenforceable provision or part thereof by a valid or enforceable provision, which shall best reflect the Parties’ original intention
and shall to the extent possible achieve the same economic result.

 

		17.8	Amendments

 

The Parties acknowledge and agree
that this Agreement may only be amended by an instrument signed by all Parties.

 

		17.9	Disclaimer

 

The Lender hereby acknowledges that
the Borrower is not subject to oversight by the Swiss Financial Market Supervisory Authority FINMA and the Loan is not protected by the
deposit protection rules pursuant to Art. 37h et seq. SBA.

 

		17.10	Form Requirements

 

This Agreement may be executed and
amended in writing and be delivered by post, courier or email; the counterpart so executed and delivered shall be deemed to have been
duly executed and validly delivered and be valid and effective for all purposes.

 

		18.	Applicable law and jurisdiction

 

This Agreement shall in all respects
be governed by and construed in accordance with Swiss law under the exclusion of its private international law provisions and international
treaties.

 

Any dispute, controversy or claim
arising out of, or in relation to, this con-tract, including the validity, invalidity, breach, or termination thereof, shall be subject
to the exclusive jurisdiction of the courts of Zug, Canton of Zug, Switzerland.

 

[signature page to follow]

 

    16

    Loan Agreement

    

 

Lender 

 

Cormorant Private Healthcare Fund IV, L.P.

 

	Signature:	/s/ Bihua Chen	 
	By: 	Cormorant Private GP IV, LLC	 
	By: 	Bihua Chen, Managing Member	 

 

Existing Lender 1 

 

	Signature:	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.	 

 

Existing Lender 2 

 

	Signature:	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology
Value Fund II, L.P.
	 

 

Existing Lender 3 

 

	Signature:	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	President BVF Inc., General Partner of BVF Partners L.P., itself sole
member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.
	 

 

    17

    Loan Agreement

    

 

Borrower 

 

MoonLake Immunotherapeutics AG

 

	Signature:	/s/ Jorge Santos da Silva	 
	Name:	Jorge Santos da Silva	 
	Title:	Chief Executive Officer and

                                 Member of the Board
	 

 

	Signature:	/s/ Matthias Bodenstedt	 
	Name:	Matthias Bodenstedt	 
	Title:	Chief Financial Officer	 

 

Investor 

 

Helix Acquisition Corp.

 

	Signature:	/s/ Andrew Phillips	 
	Name:	Andrew Phillips	 
	Title:	Chief Financial Officer 	 

 

    18

    Loan Agreement

    

 

Annex
1: Definitions

 

	Affiliates	
    shall mean any individual, firm, corporation,
    partnership, association, limited liability company, trust or any other entity that:

    a) directly
    or indirectly is controlled by or is under common control with a Party;

    b) directly
    or indirectly controls a Party;

    including, without limitation, any venture capital
    fund or registered investment company now or hereafter existing that is managed or advised by such Party or by the same advisor as such
    Party, provided, however, that the ultimate beneficial owner(s) of such Party remains at all times the ultimate beneficial owner(s) of
    the relevant individual, firm, corporation, partnership, association, limited liability company, trust or other entity.

	Agreement	shall mean this loan agreement, including its Annexes and related documents, as amended from time to time.
	Annex	shall mean an annex to this Agreement.
	Borrower	shall have the meaning given on the cover page of this Agreement.
	Business Combination Agreement	Shall have the meaning ascribed to in Preamble D.
	Change of Control	
    shall mean:

    a)  the
    acquisition of more than 50% of the Borrower’s outstanding Shares by any person or entity in any transaction or series of related
    transactions (other than as a result of bona fide equity financing purposes (including, but not limited to the Transaction Closing));
    or

    b)  a
    merger, spin-off or other type of restructuring in which the holders of the voting securities of the Borrower outstanding immediately
    prior to such transaction retain less than the majority of the total voting power represented by the voting securities of the Borrower
    or such surviving entity outstanding immediately after such transaction; or

    c)  a
    sale, lease, transfer, exclusive license or other conveyance of all or substantially all of the assets of the Borrower in an arms’
    length transaction (other than to a wholly-owned subsidiary of the Borrower or to a parent Borrower).

 

    19

    Loan Agreement

    

 

	CO	shall mean the Swiss Code of Obligations of 30 March 1911, as amended.
	Confidential Information	shall have the meaning ascribed to it in Section ‎17.2.
	Conversion	shall mean an Equity Financing Conversion or a Mandatory Conversion. 
	Conversion Price	
    shall mean:

    a)       with
    respect to an Equity Financing Conversion, the price per Conversion Share equal to 80% of the subscription price paid by the investors
    in such Equity Financing Round;

    b)       with
    respect to a Mandatory Conversion, the price per Conversion Share equal to 80% of the value obtained by dividing the Fair Market Value
    of the Borrower by the Borrower’s Fully Diluted Shares as of immediately prior to the Mandatory Conversion;

    in each case less any applicable
    tax deductions.

    If the issue price for the Conversion Shares in
    an Equity Financing Conversion is set in a currency other than the currency of the Loan, the Loan shall be converted into the currency
    of the issue price for the Conversion Shares at the official applicable exchange rate published by the Swiss National Bank (https://www.snb.ch/en/iabout/stat/statrep/id/current_interest_exchange_rates#t3)
    for the close of the business day of the day before the date of the subscription by the Lender.

	Conversion Shares	
    shall mean:

    a) in
    the case of an Equity Financing Conversion, shares of the most senior class of equity securities of the Borrower issued in the relevant
    Equity Financing Round, or at the election of the Lender, the most senior class of equity securities of the Borrower issued at such time;

    b)  in
    the case of a Mandatory Conversion, shares of the most senior class of equity securities of the Borrower issued at such time.

    In case of fractions, the resulting number of
    shares shall be rounded down to the next full number and any remaining amount shall be deemed waived by the Lender, unless the Lender
    agrees to have the number of shares being rounded up and to compensate the difference in cash.

	Equity Financing Conversion	shall mean a conversion of the Loan pursuant to Section ‎12.1.
	Equity Financing Round	shall mean the next bona fide share capital increase during which new shares of the Borrower are issued against cash to existing or new investors, excluding (i) any share capital increases in connection with the issuance of shares under the share participation plan, the employee stock option plan or any similar benefit plans of the Borrower and (ii) any and all indebtedness that may be converted into Conversion Shares (such as the Loan). 

 

    20

    Loan Agreement

    

 

	Event of Default	shall have the meaning ascribed to it in Section 7.
	Existing Lender(s)	shall have the meaning given on the cover page of this Agreement.
	Existing Loan Agreement	shall have the meaning ascribed to it in Section E.
	Exit	shall have the meaning ascribed to it in Section ‎16.
	Fair Market Value	shall mean the fair market value agreed between the Lender and the Borrower, or if the Parties cannot agree, the fair market value determined by a mutually acceptable independent auditor. If such independent expert refuses or is not able to act or if the Parties cannot agree upon such independent expert, an experienced national or international accounting firm shall be appointed by the President of the Zurich Chamber of Commerce who shall determine the fair market value on the basis of a valuation of the Borrower using methods customarily used at that time to establish the value of businesses in that industry, excluding any control premium for obtaining a majority of the voting rights in the Borrower or any block premium. The fair market value as determined by the independent expert shall be binding and final on the Parties, unless based on calculation errors, in which case the fair market value as corrected by the independent expert shall be binding. The independent expert will have the role and powers of an arbitrator within the meaning of Art. 189 of the Swiss Code of Civil Procedure (CPC).
	Financial Indebtedness	
    shall mean any indebtedness for or in respect
    of:

    a)       moneys
    borrowed; and

    b)       any
    amount raised pursuant to any note purchase facility or the issue of bonds, notes debentures or any similar instrument.

	FinSA	shall mean the Swiss Financial Services Act of 15 June 2018, as amended.
	Fully Diluted Shares	shall mean all issued shares of the Borrower together with all option or conversion rights of any kind (whether vested or not and including any authorized but unallocated rights) on an as-converted-basis.
	Investor	shall have the meaning given on the cover page of this Agreement.
	Helix	shall have the meaning given on the cover page of this Agreement.
	Lender	shall have the meaning given on the cover page of this Agreement.
	Lender PIPE Commitment	shall have the meaning ascribed to it in Section F.
	Loan	shall have the meaning ascribed to it in Section 2.
	Mandatory Conversion	shall mean a conversion of the Loan pursuant to Section ‎12.2.
	Maturity Date	shall have the meaning ascribed to it in Section 6.
	Party/Parties	shall have the meaning given on the cover page of this Agreement.
	Preamble	shall mean the preamble of this Agreement. 
	Roll-Over	shall have the meaning ascribed to it in Section ‎14.
	SBA	shall mean the Swiss Banking Act of 8 November 1934, as amended.
	Section	shall mean a section of this Agreement. 
	Share(s)	shall have the meaning given in Section C of the Preamble.
	Transaction	shall have the meaning given in Section D of the Preamble.
	Transaction Closing	shall mean the closing of the Transaction. 

 

    21

    Loan Agreement

    

 

Annex
2: Consent Declaration

 

To: Cormorant Private Healthcare Fund
IV. L.P. (the "Lender")

 

_________________________

Place, date  

 

RE: Shareholder / Option Holder Consent Declaration

 

Dear Madam or Sir:

 

I am a shareholder / holder of an option to acquire
shares of MoonLake Immunotherapeutics AG, Dorfstrasse 29, 6300 Zug (the “Company”) and I have taken note of the convertible
loan agreement you have entered into with the Company (the “Convertible Loan Agreement”) a copy of which was provided
to me.

 

I hereby acknowledge and irrevocably approve and
ratify the execution of the Convertible Loan Agreement and the discharge of the obligations of the Company thereunder.

 

Furthermore, in order to achieve the conversion,
I hereby irrevocably undertake to you and to the Company (the undertaking to the Company being a real contract in favour of third parties
in the sense of Art. 112 para 2 CO) to adopt and/or procure the adoption of the necessary resolutions of the shareholders of the Company
to effect the conversion of the loan in accordance with the terms of the Convertible Loan Agreement and to waive any priority subscription
rights (Vorwegzeichnungsrechte) and subscription rights (Bezugsrechte) to the extent necessary to allow for the full implementation
of the Voluntary Conversion or the Mandatory Conversion (both as defined in the Convertible Loan Agreement).

 

This consent declaration shall in all respects
be governed by and construed in accordance with Swiss law under the exclusion of its private international law provisions and international
treaties.

 

Any dispute, controversy or claim arising out
of, or in relation to, this consent declaration, including the validity, invalidity, breach, or termination thereof, shall be subject
to the exclusive jurisdiction of the courts of Zug, Canton of Zug, Switzerland.

 

Sincerely yours,

 

	Name of Shareholder/ Option Holder:	 	 	 
	 	 	 
	Signatures of Shareholder / Option Holder:	 	 

 

	 	 
	Name:	 
	Title:	 

 

    22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]